Windtree Therapeutics, Inc. Net Income Common

Net Income Common of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Income Common growth rates and interactive chart. Net income to common (NIC), also called net profit to shareholders, is calculated as sales minus cost of goods sold, selling, general and administrative expenses, operating expenses, depreciation, interest, taxes, and other expenses incuding preferred dividends. It is a useful number for investors to assess how much revenue exceeds the expenses of an organization.


Highlights and Quick Summary

  • Net Income Common for the quarter ending June 29, 2020 was $-9.56 Million (a 46.28% increase compared to previous quarter)
  • Year-over-year quarterly Net Income Common increased by 34.13%
  • Annual Net Income Common for 2019 was $-27.5 Million (a -20.95% decrease from previous year)
  • Annual Net Income Common for 2018 was $-34.8 Million (a 40.05% increase from previous year)
  • Annual Net Income Common for 2017 was $-24.8 Million (a -37.16% decrease from previous year)
  • Twelve month Net Income Common ending June 29, 2020 was $-30.6 Million (a 11.36% increase compared to previous quarter)
  • Twelve month trailing Net Income Common decreased by -29.45% year-over-year
Trailing Net Income Common for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-30.6 Million $-27.5 Million $-27.5 Million $-43.4 Million
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Income Common of Windtree Therapeutics, Inc.

Most recent Net Income Commonof WINT including historical data for past 10 years.

Interactive Chart of Net Income Common of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Net Income Common for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-9.56 $-6.53
2019 $-7.38 $-7.13 $-6.44 $-6.54 $-27.48
2018 $-23.27 $-3.93 $-3.05 $-4.51 $-34.76
2017 $2.47 $-7.68 $-7.28 $-12.33 $-24.82
2016 $-6.6 $-8.36 $-10.62 $-13.9 $-39.49
2015 $-10.11 $-21.56 $-11.33 $-12.18 $-55.17
2014 $-10.64 $-11.32 $-10.62 $-11.48 $-44.06
2013 $-11.73 $-12.22 $-8.63 $-12.64 $-45.22
2012 $-6.82 $-13.35 $-7.14 $-10.02 $-37.32
2011 $-4.3 $-4.75 $-8.08 $-3.84 $-20.97
2010 $-5.74 $-6.58 $-0.79 $-6.06 $-19.18

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.